Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System.

Ther Adv Neurol Disord · 2022 · PMC9551667 · PMID 36237201

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

borderline significancep = 0.053so close (0.05 < p ≤ 0.1)

In the MLR, age (odds ratio [OR]: 1.1; 95% CI: 1.07–1.3; p < 0.01), treatment with anti-CD20 therapies (4.1; 1.16–14.5; p = 0.03), and with a borderline significance also treatment with natalizumab (3.3, 0.99–10.95, p = 0.053) were significant predictors of COVID-19-related death, whereas female sex was found to be protective (0.4; 0.22–0.72; p < 0.01) ( Figure 1 ).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.